摘要
为探讨前列腺特异抗原 ( PSA)及前列腺特异抗原密度 ( PSAD)的临床应用价值 ,用放射免疫分析法测定了 2 8例前列腺癌 ( Pca)及 80例良性前列腺增生 ( BPH)患者的治疗前、后 PSA含量 ,其中 1 8例 Pca及 50例 BPH患者同时测定了 PSAD,结果 PSA诊断 Pca的灵敏度、特异性和准确度分别为 85.7%、80 .0 %及 81 .4 %。在鉴别Pca和 BPH上 PSAD优于 PSA,使假阳性率由 PSA的 2 0 %降到 6% ,但在临床应用中要注意结合其它检查进行综合分析。治疗后定期检测血清 PSA对早期发现局部复发或转移。
To study the clinical value of prostate specific antigen(PSA) and prostate specific antigen density(PSAD), the PSA levels of pre-and post-treatment were measured in 28 cases with prostate cancer(Pca) and 80 patients with benign Prostate hyperplasia(BPH). PASD was measared in 18 cases Pca and 50 cases BPH of them. The results suggest that the sensibility, specificity and accuracy of diagnosis for Pca were 85.7%, 80.0% and 81.4%, respectively. The false positive rate was 20%. PSAD is superior to PSA in distinguishing prostate cancer from benign prostate hyperplasia. The false positive rate was only 6%. But in the clinical application, we should combine PASD with other materials. The regular observation of post therapeutic PSA is of great value to the earlier discovery of local recurrence and metastasis as well as the judgement of curative effect and prognosis.
出处
《标记免疫分析与临床》
CAS
2001年第2期76-77,共2页
Labeled Immunoassays and Clinical Medicine
关键词
前列腺特异抗原
前列腺特异抗原密度
前列腺癌
良性前列腺增生
Prostate specific antigen
Prostate specitic antigen density
Prostate cancer
Benign prostate hyperplasia
